Risk and benefit of postoperative adjuvant immunothera-py for gastric cancer
DING Ming-chen
CONG lin
CAI Jie-yuan
Zhang Xiao-tian
Abstract：For postoperative adjuvant therapy in patients with locally advanced gastric cancer,immunotherapy has the potential to improve prognosis,but existing evidence still cannot shake the cornerstone position of chemotherapy.Accurately screening potential beneficiaries of immunotherapy is the key to addressing the poor efficacy of adjuvant immunotherapy in the entire population after surgery.It is recommended to first screen the population with potential immune benefits,such as EBV positive,dMMR/MSI-H,and PD-L1 high expression,based on the molecular classification and biomarkers of the tumor.Then,combined with the patient's immune therapy tolerance,postoperative pathological stage,histological classification,and economic family status,the risk and benefit ratio of immune therapy should be comprehensively evaluated to develop the best treatment plan.
Keywords：gastric cancerimmunotherapyadjuvant therapyimmune checkpoint inhibitorschemotherapy
Publication Date：2024-10-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1133-1138 )